Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03000231 · ClinicalTrials.gov registry record
Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 86
- Enrollment target
NCT03000231: Completed study, sponsored by University of Chicago.
NCT03000231 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03000231 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to compare cardio-metabolic risk, glucose tolerance, and night time blood pressure between healthy control subjects and patients with adrenal insufficiency. No intervention will be administered and the study is observational only.
Primary Outcome
On each day, the midpoint (time in hours and minutes) of the sleep period will be calculated and the variability over 1 week will be quantified by the standard deviation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-10 |
| Est. Completion | 2023-12 |
What the finished NCT03000231 record still lists
NCT03000231 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03000231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03000231 about?
NCT03000231 is a clinical study titled "Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency". The purpose of this study is to compare cardio-metabolic risk, glucose tolerance, and night time blood pressure between healthy control subjects and patients with adrenal insufficiency. No intervention will be administered and the study is observational only.
What is the current status of trial NCT03000231?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2015-10. Estimated completion is 2023-12.
Who is sponsoring clinical trial NCT03000231?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia